TY - JOUR
T1 - Oncolytic potential of E1B 55 kDa-deleted YKL-1 recombinant adenovirus
T2 - Correlation with p53 functional status
AU - Lee, Heuiran
AU - Kim, Jaesung
AU - Lee, Boyoung
AU - Chang, Jin Woo
AU - Ahn, Joongbae
AU - Park, Joon Oh
AU - Choi, Jene
AU - Yun, Chae Ok
AU - Kim, Byung Soo
AU - Kim, Joo Hang
PY - 2000
Y1 - 2000
N2 - YKL-1, E1B 55 kDa-deleted recombinant adenovirus vector, capable of harboring a transgene casette of up to 4.9 kb, was newly constructed by reintroducing E1A and E1B 19 kDa into E1/E3-deleted adenoviral vector with a homologous recombination in E. coll. Virus replication and cytotoxicity were dramatically attenuated in all 3 different types of normal human cells. In contrast, YKL-1 efficiently replicated and induced cytotoxicity in most cancer cells, especially Hep3B and C33A cells with an inactivating p53 mutation. However, both H460 and HepG2 exhibited intermediate sensitivity to YKL-1, which was between that of Hep3B or C33A and normal human cells. The YKL-1 and DNA damaging agent, camptothecin effectively induced p53 in H460 and HepG2 as well as in normal cells. Furthermore, YKL-1 effectively prohibited both Hep3B and C33A tumor growth in nu/nu mice in a dose-dependent manner. H/E staining and TUNEL assay indicated a largely distributed necrotic area and apoptosis on its periphery. This study, therefore, indicates that YKL-1, possesses promising potential as an oncolytic adenoviral vector, which acts partially in a p53-dependent manner. (C) 2000 Wiley-Liss, Inc.
AB - YKL-1, E1B 55 kDa-deleted recombinant adenovirus vector, capable of harboring a transgene casette of up to 4.9 kb, was newly constructed by reintroducing E1A and E1B 19 kDa into E1/E3-deleted adenoviral vector with a homologous recombination in E. coll. Virus replication and cytotoxicity were dramatically attenuated in all 3 different types of normal human cells. In contrast, YKL-1 efficiently replicated and induced cytotoxicity in most cancer cells, especially Hep3B and C33A cells with an inactivating p53 mutation. However, both H460 and HepG2 exhibited intermediate sensitivity to YKL-1, which was between that of Hep3B or C33A and normal human cells. The YKL-1 and DNA damaging agent, camptothecin effectively induced p53 in H460 and HepG2 as well as in normal cells. Furthermore, YKL-1 effectively prohibited both Hep3B and C33A tumor growth in nu/nu mice in a dose-dependent manner. H/E staining and TUNEL assay indicated a largely distributed necrotic area and apoptosis on its periphery. This study, therefore, indicates that YKL-1, possesses promising potential as an oncolytic adenoviral vector, which acts partially in a p53-dependent manner. (C) 2000 Wiley-Liss, Inc.
UR - http://www.scopus.com/inward/record.url?scp=0033809680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033809680&partnerID=8YFLogxK
U2 - 10.1002/1097-0215(20001101)88:3<454::AID-IJC19>3.0.CO;2-T
DO - 10.1002/1097-0215(20001101)88:3<454::AID-IJC19>3.0.CO;2-T
M3 - Article
C2 - 11054676
AN - SCOPUS:0033809680
SN - 0020-7136
VL - 88
SP - 454
EP - 463
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 3
ER -